







In collaboration with



DigiCore

On April 1st 2021 a new Organisation focused on producing cancer real world evidences came into legal being – the DIGital Institute for Cancer Outcomes REsearch (DIGICORE).

DIGICORE's objectives are to help the cancer community for the digital revolution that will transform research through the routine use of electronic health records (EHR) and molecular diagnostic information (MDX) for trial automation, outcomes research, digital diagnostics and care quality management.

DIGICORE is set up as a European Economic Interest Grouping with 18 prominent cancer centres and 2 cancer networks, UNICANCER and Alleanza Contro il Cancro, as Members. Two commercial partners have joined this

ambitious endeavour: IQVIA, the leading contract research organisation and Illumina, the global leader in DNA sequencing and bioinformatics. These commercial parties have been chosen to ensure medical hypothesis neutrality. This event will catalyse collaboration between European cancer centres and institutes on future research opportunities, including as part of the European Cancer Mission. DIGICORE is uniquely placed in Europe, in partnership with other OECI cancer centres, to lead the generation of clinical insights and infrastructure relevant to the Cancer Mission priorities, in the fight against cancer and for improved patient outcomes.

The European Cancer Mission aims to deliver collaborative research at a scale that will transform our treatment and understanding of cancer. We are at the dawn of a digital revolution in the research opportunities that real world evidence (RWE) enables. The increasing understanding of the molecular mechanisms underlying disease and the scaling up of accessibility to high quality clinical data are key aims for the DIGICORE approach.

The demand on us all as professionals in cancer care, is to work more collectively as a network to prepare for better re-use of high-quality routine EMR data in protocolised research at scale. Digital methods have the potential to transform care quality management and the implementation of National Beating Cancer plans as well as contributing to multi-national research.

The vision for DIGICORE is to take a position of leadership in Europe in this digital revolution. We warmly invite you to join us in this challenge and welcome your active participation in this symposium. The schedule is one of thought-provoking plenaries on November 3rd and 4th, supported by dinners arranged to promote networking. On Friday 5th, there will be greater opportunity for synthesis of the content in discussion and planning towards successful collaborations within the network. Delegates from centres that are not yet members of DIGICORE are very welcome as observers to this session, but we encourage application to DIGICORE for greater involvement.

Wednesday November 3rd

On November 3rd and 4th the Event is open to DIGICORE members and to colleagues from the OECI and other cancer centres/institutes that have not committed to joining DIGICORE yet.

11.00 - 12.30 Introductions and Context

- 11.00 11.30 Welcome Thierry Philip
- 11.30 12.00 DIGICORE's vision for collaborative RWE Gennaro Ciliberto

12.00 - 12.30 The context to "Connect to Win".

Serena Di Cosimo Which cancer centres/institutes are in, with what patient cohorts, major research programmes and key researchers?

Institut national des jeunes sourds de <u>Paris</u>

(Amphithéâtre de l'abbé

254 rue Saint Jacques

(INJS)

de l'Epée)

75005 Paris

12.30 - 13.30 Lunch

13.30 - 18.00 Preparing for the European Cancer Mission

13.30 - 14.10 What is the European Cancer Mission and what changes to research culture are required to succeed?

Keynote: Bettina Ryll

The genesis of the Cancer Mission, its main themes and what changes the European Commission and the cancer Mission Board wish to see to research culture to improve patient impact

14.10 - 14.20 **Q&A**

14.20 - 15.00 **RWE readiness across the network: the results and implications** *Piers Mahon*

Presentation of results from preparatory surveys with cancer centres on i) our collective "readiness" for real world evidence and ii) our collective research interests within the European Cancer Mission recommendations. Introduction to the Bronze – Silver – Gold RWE readiness framework and its role in RWE research planning

15.00 - 16.00 Panel discussion: Getting ready for RWE - the Institutional Journey

Panel (TBC) including: Bettina Ryll, Geoff Hall, Xose Fernandez

Facilitated by Piers Mahon

Panelists from the more digitally mature cancer centres will discuss their institution's multi-year path to routine high-quality clinical data, and the information governance and legal solutions of their Institutions

16.00 - 16.20 Coffee break

16.20 - 17.00 **Deploying data to beat cancer**

Keynote: **Mark Lawler** Initiatives to harness the power of health data for research, NCPs, level precision medicine approaches, and patient-centered care

17.00 - 17.40 Data-driven approaches against COVID in Europe: lessons for the Cancer Mission

Janne Vehreschild

Europe's COVID response has made full use of a range of real world evidence. How clinical informatics has driven the COVID response across Europe, drawing on the experience of the German National COVID-19 Cohort (NAPKON) and the Lean European Survey on SARS-CoV-2 (LEOSS). Employing health data from discovery to practice change

17.40 - 18.00 **Q&A**

Thursday November 4th

On November 3rd and 4th the Event is open to DIGICORE members and to colleagues from the OECI and other cancer centres/institutes that have not committed to joining DIGICORE yet.

Institut national des jeunes sourds de Paris (INJS) (Amphithéâtre de l'abbé de l'Epée) 254 rue Saint Jacques 75005 Paris

08.30 - 13.00 Academic Real World Evidence Showcase

Chair: Serena Di Cosimo

Introduction to the diverse research programmes that will be showcased

08.40 - 09.15 The state of the art in multi-country European Cancer RWE Geoff Hall

The Ovarian Real World International Collaboration (ORWIC) as an example of enhanced from EMR, multi-center, multi-country natural history and outcomes study run without study specific consent or the sharing of patient level data

09.15 - 09.50 **A view from France**

Anne-Laure Martin

The French Epidemiological Strategy and Medical Economics (ESME) database and the UNICANCER experience

09.50 - 10.25 A view from Germany

Martin Peuker

Charite Berlin has taken a two value strategy, co-developing a data lake (including broad but less high quality data for exploratory use), with a medical device platform (including key data needed for regulatory grade uses such as care delivery or translational research on regulated products)

10.25 - 10.40 The EURACAN network

Jean-Yves Blay

Learning from the experience of networking expert centres for the treatment of rare solid tumours

- 10.40 11.00 **Q&A**
- 11.00 11.25 Coffee break
- 11.25 12.00 A view from Italy

Piergiuseppe Pelicci

Learning from the experience of Alleanza Contro il Cancro's Health Big Data project

12.00 - 12.40 **The Norwegian Cancer Precision Medicine Implementation Initiative – a prototype learning ecosystem for precision oncology** *Kjetil Tasken*

Norway has built a prototype learning ecosystem covering i) InPreD diagnostic infrastructure, ii) the IMPRESS-Norway national clinical trial iii)the CONNECT Public-Private Partnership and iv) via our national registries a path to a learning ecosystem. Prof. Tasken will talk about the progress made so far, and the lessons for others as they build towards the same goals

12.40 - 12.55 **Q&A**

12.55 - 13.45 Lunch

13.45 - 16.45 Commercial Real World Evidence Showcase

13.45 - 14.15 The role of research methods innovation in scientific breakthroughs

Chair: Piers Mahon

Methods innovation has historically driven transformative science. Dr. Mahon will introduce the revolution in RWE from this perspective, and explain why a CRO like IQVIA is interested in academic partnership to develop such novel research methods

14.15 - 14.45 Enhanced studies for commercial RWE for evidence planning and HEOR planning *Kirill Dushkin*

Introduction to the enhanced study concept using I/O Optimise: an extended multi-centre/institute enhanced study or evidence platform in NSCLC. Enhanced studies place the least technology or information governance burden on a centre and so are suitable for "Bronze" level centres or better

14.45 - 15.15 Cancer OMOP studies: opportunities for global collaboration in EMR-as-Database studies Christian Reich

GOMOP studies are the most common form of database study looking at structured data conformed to a common data model. Dr. Reich will introduce these studies using the Cancer-OMOP programme from ODHSI for which IQVIA is a founding industrial partner (and coleading the cancer OMOP extension). Database studies require a centre to have implemented OMOP, typically around the "Silver" level of RWE readiness

Thursday November 4th

On November 3rd and 4th the Event is open to DIGICORE members and to colleagues from the OECI and other cancer centres/institutes that have not committed to joining DIGICORE yet.

Institut national des jeunes sourds de Paris (INJS) (Amphithéâtre de l'abbé de l'Epée) 254 rue Saint Jacques 75005 Paris

15.15 - 15.45 **RWE using patient level data for precision oncology and regulatory** filing

Benedikt Maissenhalter

IQVIA is leading projects to both generate narrow molecular (e.g. KRAS G12C) and case matched cohorts from European EHR data for global pharma, often for regulatory submission to both EMA and FDA. IQVIA is helping both regulators develop their approaches to the use of RWE in regulatory approvals. These methods place the highest burden on a cancer centre, and generally are only possible at "Gold" level centres

15.45 - 16.00 **Q&A**

16.00 - 16.15 Coffee break

16.15 - 16.45 Advanced oncology real world evidence programmes in America – lessons for Europe

Keynote: Nancy Dreyer

Overview of the major precision oncology real world evidence programmes in the United States, including IQVIA's work with Friends of Cancer Research, the major precision oncology networks and the work IQVIA is doing with the FDA to shape regulatory uses of real world evidence.

16.45 - 18.00 Transformative technologies & concepts to support the Cancer Mission

Piers Mahon

Introduction to the role of technology in supporting high quality real world research and routine data and three twenty minute presentations on key emerging technologies. Topics will cover:

Technologies for digital patient finding

Richard Child

The role of minimal data models like OSIRIS to simplify oncology RWE

Julien Guérin

End-to-end solutions for mobilizing routine CGP test data for research Volker Liebenberg

Friday November 5th

08.30 - 13.00 Restricted "DIGICORE only Session"

strategy.

Institut Henri Poincaré Amphithéâtre Darboux 11 rue Pierre et Marie Curie 75005 Paris

This session is designed for DIGICORE members, associate members and those in the process of applying for membership to plan for collaborative initiatives for the Cancer Mission and outline 2022

Delegates from other centres are welcome as observers to understand the benefits of DIGICORE membership.

Application to join DIGICORE: https://digicore-cancer.eu/Page.aspx?name=JOIN

There will be opportunity during the symposium to have 1:1 consultations on a number of topics raised, including membership of various networks and consortia represented. Please see your registration packs for details of how to schedule a 30-minute consultation and we will try to

accommodate you with the

avaialble capacity.

List of speakers

Richard Child

IQVIA - Health Research Ecosystem Lead, London (UK)

Gennaro Ciliberto

Regina Elena National Cancer Institute, Rome (Italy) - President of DIGICORE

Serena Di Cosimo

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, (Italy) - DIGICORE Academic Research Manager

Nancy Dreyer

Chief Scientific Officer and Sr Vice President at IQVIA (Massachusetts, USA) and Adjunct Prof of Epidemiology (University of North Carolina)

Kirill Dushkin

IQVIA - Deputy project lead for I/O Optimise, London (UK)

Xose Fernandez

Chief Data Officer, Insitut Curie, Paris (France) – Treasurer of DIGICORE

Julien Guérin

Institut Curie, Paris (France) - Head of Health Data Factory

Geoff Hall

Chief Clinical Information Officer (Leeds Teaching Hospitals NHS Trust), Prof. of Digital Health & Cancer Medicine (Leeds University, UK)

Mark Lawler

Associate Pro-Vice-Chancellor and Professor of Digital Health (Queens University Belfast, UK), Associate Director of Health Data Research Wales-Northern Ireland, Scientific Director of DATA-CAN

Volker Liebenberg

Illumina - Head of Medical Affairs -Berlin (Germany)

Piers Mahon

IQVIA - Senior Principal and European Leader - DIGICORE Commercial Research Manager, London (UK)

Benedikt Maissenhalter

IQVIA - Project lead on multiple External Comparators for FDA filing, London (UK)

Anne-Laure Martin

Director of Development, Strategic Alliance and Partnership at UNICANCER

Pier Giuseppe Pelicci

Chairman and Executive Director of Istituto Europeo di Oncologia, Professor of Experimental Oncology (Università degli Studi di Milano), President of the European School of Molecular Medicine and Scientific Director of Alleanza Contro il Cancro

Martin Peuker

Charité Hospital - Head Business Division IT (CIO of the year 2020), Berlin (Germany)

Thierry Philip

OECI President - President of the Executive Board of Institut Curie, Paris (France)

Christian Reich

IQVIA - Global Leader for OMOP studies, London (UK)

Bettina Ryll

ESMO Member of the Cancer Mission Board, Uppsala (Sweden)

Kjetil Taskén

Director of the Institute of Cancer Research (Oslo University Hospital), National Director for Norway for EU-OPENSCREEN, Prof of Medicine (University of Oslo, Norway)

Janne Vehreschild

Research Group Leader German Centre for Infection Research (DZIF), Dept Internal Medicine (Cologne), Prof of Translational Cohorts in HIV Research (University of Cologne, Germany)

The venue

November 3rd and 4th

Institut national des jeunes sourds de Paris (INJS) 254 rue Saint Jacques 75005 Paris Amphithéâtre de l'abbé de l'Epée.

November 5th

Institut Henri Poincaré (IHP) 11 rue Pierre et Marie Curie 75005 Paris Amphithéâtre Darboux.

List of suggested Hotels

HOTEL SEROTEL LUTECE****

2 rue Berthollet, 75005 Paris - Tel: +33 1 43 36 26 30 Mail: hotelserotel@gmail.com https://www.hotellutece.com

RELAIS ST JACQUES****

3 rue de l'Abbé de l'Epée, 75005 Paris - Tel: +33 1 53 73 26 00 http://hotelrelaissaintjacques.com/fr/index.php

HOTEL DES JARDINS DU LUXEMBOURG***

5 impasse Royer Collard, 75005 Paris - Tel: +33 1 40 46 08 88 https://www.hoteljardinsluxembourg.com

QUARTIER LATIN ***

108 rue Monge, 75005 Paris - Tel: +33 1 47 07 19 04 Mail: reception@hotelfrancequartierlatin.com https://hotelfrancequartierlatin.com

HOTEL PORT ROYAL***

108 rue Monge, 75005 Paris - Tel: +33 1 47 07 19 0 Mail: reception@hotelfrancequartierlatin.com https://hotelfrancequartierlatin.com

Health rules

To enter the congress venues, participants must exhibit a green pass or a negative molecular test taken at most 48 hours before arrival.

Please check up to date restrictions for entry into France at https://www.diplomatie.gouv.fr/ en/coming-to-france/coronavirus-advice-forforeign-nationals-in-france

Scientific Secretariat

Gennaro Ciliberto Serena Di Cosimo Xose Fernandez Piers Mahon Thierry Philip

Organising Secretariat

Claudio Lombardo Giorgia Pesce Roxana Plesoianu Catherine Manceau Will Sopwith

Info at: info@digicore-cancer.eu

Connect to Win is realised thanks to the kind educational grant of:



IQVIA is a world leader in using data, technology, advanced analytics, and expertise to help customers drive healthcare forward. Together with the companies we serve, we are enabling a more modern and effective healthcare system and creating breakthrough solutions that transform business and patient outcomes.

